GN

Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, University of Leicester, Survival, FRCP, ALPN, GN, EGFR, Biomarker, Fig, Nephrology, PMN, MD, Inflammation, Cytokine, Doctor of Philosophy, Glomerular filtration rate, Immunoglobulin A, American Society of Nephrology, Multimedia, Society, BAFF, Glossary of education terms (G–L), Disease, Barratt, ASN, Webcast, Emory University School of Medicine, University, Immunoglobulin G, Autoimmunity, Glomerulonephritis, Patient, Infection, Vaccine, Sewage treatment, Pharmaceutical industry, Research, IgA nephropathy, Proteinuria, Alpine, Medicine, UPCR

RUBY-3 is a multiple ascending dose, multi-cohort, open label, phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, where povetacicept is administered subcutaneously (SC) once every four weeks for up to 48 weeks.

Key Points: 
  • RUBY-3 is a multiple ascending dose, multi-cohort, open label, phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, where povetacicept is administered subcutaneously (SC) once every four weeks for up to 48 weeks.
  • A higher dose of povetacicept, 240 mg SC every four weeks, continues to enroll, with initial data expected in 1H 2024.
  • A higher dose of povetacicept 240 mg every four weeks is currently being explored and will be of great interest.
  • “We eagerly await the initial data from the next 240 mg dose level in the first half of 2024.

Venatorx Announces Presentation of Analysis of Cefepime-Taniborbactam in vitro Activity against Clinically Significant Gram-Negative Bacteria Isolated from Patients with Cancer at IDWeek 2023

Retrieved on: 
Monday, October 16, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, PWC, Infection, Incidence, CRE, Gram-negative bacteria, Extended-spectrum penicillin, Bacteria, GN, Risk, Escherichia coli, UICC, Enterobacterales, Ceftolozane/tazobactam, Cancer, MD Anderson Cancer Center, Pseudomonas aeruginosa, MDR, University, Ceftazidime/avibactam, Medication, ESBL, Serine, Patient, AMR, Pharmaceutical industry

Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with drug-resistant bacterial infections and hard-to-treat viral infections, today announces the presentation of data during IDWeek 2023 , October 11-15, 2023, in Boston, MA on the in vitro activity of cefepime-taniborbactam, an investigational antibacterial agent, in comparison to other antibiotics against clinically significant gram-negative bacteria isolated from patients with cancer.

Key Points: 
  • Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with drug-resistant bacterial infections and hard-to-treat viral infections, today announces the presentation of data during IDWeek 2023 , October 11-15, 2023, in Boston, MA on the in vitro activity of cefepime-taniborbactam, an investigational antibacterial agent, in comparison to other antibiotics against clinically significant gram-negative bacteria isolated from patients with cancer.
  • The bacterial isolates tested included Extended Spectrum β-lactamase (ESBL) producing Enterobacterales and Carbapenem Resistant Enterobacterales (CRE) isolates, and MDR Pseudomonas aeruginosa.
  • In the study, cefepime-taniborbactam demonstrated higher in vitro activity than the tested comparators.
  • While cefepime-taniborbactam has not yet been approved for clinical use, only 3 of the 270 isolates (1.1%; 2 CRE Escherichia coli and 1 MDR P. aeruginosa) were found to be resistant to cefepime-taniborbactam at its provisional breakpoint.

Alpine Immune Sciences to Present Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late Breaker Poster Session at American Society of Nephrology Kidney Week 2023

Retrieved on: 
Friday, October 13, 2023
Oncology, Medical Devices, Health, General Health, Pharmaceutical, Biotechnology, Emory University School of Medicine, IgA nephropathy, Autoimmunity, GN, ALPN, Society, ASN, Immunoglobulin A, American Society of Nephrology, Inflammation, Pharmaceutical industry, Medicine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present initial clinical data from RUBY-3, a phase 1b/2a study of povetacicept in autoimmune glomerulonephritis including IgA nephropathy, in a late breaking poster presentation at the American Society of Nephrology (ASN) Kidney Week, November 1-5, 2023 in Philadelphia, Pennsylvania.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present initial clinical data from RUBY-3, a phase 1b/2a study of povetacicept in autoimmune glomerulonephritis including IgA nephropathy, in a late breaking poster presentation at the American Society of Nephrology (ASN) Kidney Week, November 1-5, 2023 in Philadelphia, Pennsylvania.
  • Following the poster presentation, the Company will host an investor event after the close of the market.
  • Poster Title: Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoantibody-Associated Glomerulonephritis (GN)
    Presenter: James Tumlin, M.D., Professor of Medicine at Emory University School of Medicine, Founder and CEO of NephroNet Clinical Trials Consortium

Beltone Unveils a New Generation of Hearing Solutions with Beltone Serene

Retrieved on: 
Thursday, September 28, 2023
Ear, Life, Hearing loss, Airport, IOS, NPS, Customer service, Restaurant, Hearing, RIE, Kool-Aid, GN, Bluetooth, Bluetooth Special Interest Group, Dentistry, Music, Electric battery, Beltone, Newsweek

CHICAGO, Sept. 28, 2023 /PRNewswire/ -- Beltone, named one of America's Best Retailers and Customer Service for Hearing Care by Newsweek, announced its latest innovation in hearing care – the new Beltone Serene™ hearing aid. This new device comes in two non-rechargeable receiver-in-ear (RIE) styles and a brand new microRIE, which is Beltone's tiniest rechargeable hearing aid yet. The Beltone Serene hearing aid offers a range of advanced benefits to individuals with mild to profound hearing loss. It provides natural sound, exceptional speech understanding, and all-day comfort in a discreet design. This device is also perfect for individuals with single-sided deafness, as it comes with a new wireless CROS transmitter that routes sound from the poorer ear to the better ear to ensure greater audibility all around, so users never miss a moment.

Key Points: 
  • The Beltone Serene hearing aid offers a range of advanced benefits to individuals with mild to profound hearing loss.
  • "Beltone Serene is not just a hearing aid, it's a game-changer for those with hearing loss."
  • Additionally, Beltone will also be releasing a compatible new TV-Streamer+ , which allows users to stream audio directly from their TV to their Beltone Serene hearing aids.
  • "Beltone Serene is not just a hearing aid, it's a game-changer for those with hearing loss," explains David Molella, President of Beltone North America.

GN Hearing pioneers the next era of hearing through sound, design and connectivity with the launch of ReSound Nexia

Retrieved on: 
Thursday, September 28, 2023
Beltone, Communication, Mechanics, Hearing loss, Noise, Life, Friends, Hearing, Speech, Chevrolet Nexia, Airport, NPS, Bluetooth Special Interest Group, Restaurant, RIE, GN, Kool-Aid, Bluetooth, Peter Hancock (professor), Family, Personal protective equipment, Electric battery, Mobile phone, Cassette tape, Music

BALLERUP, Denmark, Sept. 28, 2023 (GLOBE NEWSWIRE) -- GN Hearing, the global leader in hearing aid innovation, today announces the launch of its next generation hearing aid family, ReSound Nexia, including two non-rechargeable RIE models and a new rechargeable microRIE.

Key Points: 
  • BALLERUP, Denmark, Sept. 28, 2023 (GLOBE NEWSWIRE) -- GN Hearing, the global leader in hearing aid innovation, today announces the launch of its next generation hearing aid family, ReSound Nexia, including two non-rechargeable RIE models and a new rechargeable microRIE.
  • The microRIE is GN Hearing’s smallest and most comfortable style ever, packed with advanced technology and features.
  • In addition, ReSound Nexia connects with AuracastTM broadcast audio enabling people with hearing loss to benefit from this new and exciting advancement in connectivity.
  • Scott Davis, who will be leading GN's hearing business from 1st October, explains: “ReSound Nexia represents a significant leap forward in hearing aid technology.

Galley Equipment Market to grow by USD 2.74 billion from 2022 to 2027, Growing demand for lightweight galley equipment to drive the growth- Technavio

Retrieved on: 
Tuesday, September 12, 2023
Galley, Sample, Food, Raytheon Technologies, LCC, Aviation, YOY, USD, Hygiene, Nature, GN, Miele, Growth, UAV, Bucher, Geography, Airline

NEW YORK, Sept. 12, 2023 /PRNewswire/ -- The galley equipment market is expected to grow by USD 2.74 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Sept. 12, 2023 /PRNewswire/ -- The galley equipment market is expected to grow by USD 2.74 billion from 2022 to 2027.
  • The growing demand for lightweight galley equipment is a key factor driving market growth.
  • The report analyses the market size and growth and provides accurate predictions on the growth of the market.
  • Rising demand for cost-effective virtual training in the aviation industry is expected to drive the growth of the market during the forecast period.

Sidus Space Reports Record Q2 2023 Gross Margin

Retrieved on: 
Monday, August 14, 2023
Data Management, Technology, Satellite, Aerospace, Manufacturing, Hardware, Quarter, Defense, ATLAS, Hello English (government program), Parsons, SOLAR, L3Harris Technologies, AOS, Sale, GN&C, MOU, Airbus, GN, Artificial intelligence, MEMS, Earth observation, Growth, SpaceX, Communications satellite, Tutoring, Video game, Cryptocurrency, Arrow, Sidus

(NASDAQ:SIDU) (the “Company” or “Sidus”), a Space and Data-as-a-Service satellite company, announces its financial results and is providing a business update for the second quarter ending June 30, 2023.

Key Points: 
  • (NASDAQ:SIDU) (the “Company” or “Sidus”), a Space and Data-as-a-Service satellite company, announces its financial results and is providing a business update for the second quarter ending June 30, 2023.
  • The increase in gross margin was the result of an increase in our satellite revenue.
  • For the six months ended June 30, 2023 our satellite revenue was over 100% higher than full year 2022,” said Carol Craig, Founder and CEO of Sidus.
  • The increase in gross profit margin was primarily attributed to the mix of contracts and an increase in our higher margin satellite business.

York Space Systems Acquires Emergent Space Technologies

Retrieved on: 
Wednesday, June 7, 2023
Intelligence, Orbit, United States Department of Defense, Emergent, Government, GN&C, Acquisition, NASA, GN, Control, Growth, Navigation, Intelligence community, United States Intelligence Community, PNT, Management, Guidance, MD

DENVER, June 7, 2023 /PRNewswire/ -- York Space Systems (York), a Denver-based aerospace company dedicated to the rapid deployment of complete space mission solutions, today announced the company has completed the acquisition of Emergent Space Technologies, Inc. (Emergent), a leading aerospace technology company focused on developing and fielding mission software and Guidance, Navigation and Control (GN&C) solutions for multi-spacecraft missions.

Key Points: 
  • Acquisition strengthens York's software capabilities, enhances mission design
    DENVER, June 7, 2023 /PRNewswire/ -- York Space Systems (York), a Denver-based aerospace company dedicated to the rapid deployment of complete space mission solutions, today announced the company has completed the acquisition of Emergent Space Technologies, Inc. (Emergent), a leading aerospace technology company focused on developing and fielding mission software and Guidance, Navigation and Control (GN&C) solutions for multi-spacecraft missions.
  • Emergent's nationally recognized software engineering processes will enhance York's mission solution designs for DoD, civil, and intelligence community programs.
  • "Emergent's 20-year legacy of delivering groundbreaking space system software complements York's relentless focus on rapidly delivering space systems to orbit.
  • "With the rapid commoditization of satellite hardware, the country's competitive advantage in space is in the mission software, smart networks, and edge processing.

Where does the 'ñ' come from? The history of a very special Spanish letter

Retrieved on: 
Thursday, June 1, 2023
Adoption, Philippines, Atmosphere, N, Vigna, Ink, Wise, Abbreviation, Nose, Tesoro, GN, Sound, Royal Spanish Academy, Paper, Letter, Tongue, Book, Film industry, Explosive, Cochineal, Aluminium

Why don’t we find the letter ñ in other languages in which the sound does appear?

Key Points: 
  • Why don’t we find the letter ñ in other languages in which the sound does appear?
  • The origin of the sound
    The letter ñ represents a sound that did not exist in Latin, but is found in most Romance languages (including Italian, Portuguese, French and Spanish).
  • This is the case in año (Spanish), which comes from the Latin annus, or sueño (Spanish), sogno (Italian) or sohno (Portuguese), which come from the Latin somnu.
  • Although Spain do not have the exclusivity of the ñ, it is undoubtedly an icon of Spanish in the world.

Sidus Space, Inc. Reports Q1 2023 Financial Results

Retrieved on: 
Monday, May 15, 2023
Telecommunications, Satellite, Data Management, Engineering, Technology, Aerospace, Manufacturing, Mobile, Wireless, Exercise, Common stock, ASTRA, IR, Employment, United Netherlands (organization), MEO, Defense, Calendar, Institute for Space and Defense Electronics, TNO, Data collection, L3Harris Technologies, AIS, Government, KSAT, Sidus, GN&C, GEO, MOU, LEO, MCC, Artificial intelligence, GN, Freedom Lite SS-11 Skywatch, SpaceX, Robotics, Communications satellite, Video game, Mars, Moon

(NASDAQ:SIDU), a Space and Defense-as-a-Service satellite company focused on commercial satellite design, manufacture, launch, and data collection, today announced financial results for the first quarter ending March 31, 2023 and provided a business update.

Key Points: 
  • (NASDAQ:SIDU), a Space and Defense-as-a-Service satellite company focused on commercial satellite design, manufacture, launch, and data collection, today announced financial results for the first quarter ending March 31, 2023 and provided a business update.
  • Sidus will webcast a conference call to discuss the results on May 15, 2023 at 9:00 am Eastern Time.
  • “We are excited about the future of our company,” said Teresa Burchfield, Chief Financial Officer of Sidus Space.
  • Financial Highlights for the quarter Ending March 31, 2023
    Revenue increased to $2,263,627 for the quarter ended March 31, 2023, compared to $1,799,335 for the same period in 2022.